BCL2 and acute lymphoblastic leukemia: CREBBP LOF profoundly alters metabolism and upon BCL2 inhibition results in ferroptotic cell death, which can be phenocopied by pharmacological CREBBP inhibition in genetically diverse B-ALL cell lines, providing a readily translatable synergistic drug combination for B-ALL more broadly.